Dogs get a brain tumor much like human meningioma
Original title: A comparative evaluation of canine meningioma supporting the canine patient as a naturally occurring animal model for human meningioma: a report from the NCI Comparative Brain Tumor Consortium (CBTC) meningioma pathology board.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was a study of tumors in dogs, not a treatment tested in people.
The short version
Dogs naturally get a brain tumor called meningioma, and experts found it looks a lot like the human version.
What was studied. A board of animal pathologists and human brain pathologists reviewed 190 cases of meningioma in dogs. They compared the tumor tissue to human meningioma and sorted the dog tumors using the human grading rules from the 2016 World Health Organization system.
What they found. Most of the dog tumors, 140 of 190, were the meningothelial type. Using the human rules, 109 of 190 were called grade 2, 79 were called grade 1, and two were called grade 3. But the grade did not line up with how the dogs did. In the smaller groups with outcome information, 37 dogs and 84 dogs, grade 1 and grade 2 tumors did not lead to clearly different outcomes.
What this means, and what it doesn't
What it could mean: Dogs may be a useful stand-in for studying human meningioma, since they get the tumor on their own. That could help researchers learn about the disease. The authors also say dogs need their own grading system, not the human one.
What it doesn't mean: This is not a treatment, and no drug or therapy was tested here. It is a study of tumor tissue in dogs, not in people. Nothing here changes your care today, and it is not a promise of a cure. The authors say larger studies in dogs are still needed.
Source: PubMed, July 28, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.